Further, in a multicenter study, patients with stage IIIB/IIIC melanoma and cutaneous/subcutaneous injectable metastases received weekly intra-tumoral injections of L19-IL2 for 4 consecutive weeks. This evidence concerns the gene IL2 and melanoma.